JUPITER NEUROSCIENCES, INC.
No SEC Form 4 filings for $JUNS in the last 30 days.
See all $JUNS insider activity →Jupiter Neurosciences (JUNS) reported a Q2 2026 net loss of $2.27M, slightly wider than last year's $2.25M. Per-share loss narrowed to $4.08 from $5.09. Product revenue was $0.02M, up from zero. The company priced a $2M direct offering of 307,692 shares, expected to close August 24, 2026. Cash reserves were $1.52M as of June 30, 2026. Shares closed at $6.20, up 19.92%.
Jupiter Neurosciences (JUNS) will implement a 1-for-75 reverse stock split effective Aug. 6, 2026, after shareholder approval on July 22. The company says it aims to raise the per-share price to regain Nasdaq minimum bid compliance. Shares fall from about 57.76M to ~770,081; no fractional shares, cash paid based on Aug. 6 close.
JUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001679628 0001679628 2026-07-28 2026-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Over the past 7 days, alphai's AI scored 1 news story mentioning JUNS (JUPITER NEUROSCIENCES, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent JUNS coverage spans corporate actions, mergers & acquisitions and financial news.
The $2 M raise may provide short‑term liquidity but is modest relative to cash needs, likely limiting upside.
Reverse split is a near-term liquidity and compliance catalyst that can mechanically affect per-share pricing and investor perception, but it does not change underlying fundamentals.
The filing confirms ongoing dilutive equity issuance under a standby purchase agreement, which can pressure near-term per-share metrics and sentiment.
The filing confirms shareholder approval for a reverse split (1:10 to 1:100) and additional equity plan shares, plus ratification of auditors and director elections.
The ALA-002 licensing deal expands Jupiter from a single Phase 2 Parkinson’s program into a dual clinical-stage CNS pipeline, creating a new valuation driver tied to milestones and future trial execution.
alphai scores every news story that mentions JUNS with an AI model for sentiment and relevance, and aggregates insider trades from JUPITER NEUROSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jupiter Neurosciences (JUNS) reported a Q2 2026 net loss of $2.27M, slightly wider than last year's $2.25M. Per-share loss narrowed to $4.08 from $5.09. Product revenue was $0.02M, up from zero. The company priced a $2M direct offering of 307,692 shares, expected to close August 24, 2026. Cash reserves were $1.52M as of June 30, 2026. Shares closed at $6.20, up 19.92%.
1 min readJupiter Neurosciences (JUNS) will implement a 1-for-75 reverse stock split effective Aug. 6, 2026, after shareholder approval on July 22. The company says it aims to raise the per-share price to regain Nasdaq minimum bid compliance. Shares fall from about 57.76M to ~770,081; no fractional shares, cash paid based on Aug. 6 close.
2 min readJUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001679628 0001679628 2026-07-28 2026-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
4 min readJUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001679628 0001679628 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readIPO Edge hosted a fireside chat with Jupiter Neurosciences (Nasdaq: JUNS) CEO Christer Rosén and President Alison Silva. Jupiter said it signed a definitive licensing deal with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented MDMA formulation, worth up to $100 million with milestones. The company added ALA-002 to its Phase 2 Parkinson’s program and discussed trial and regulatory outlook.
4 min readJupiter Neurosciences licensed exclusive US rights to MDMA-based ALA-002 from PharmAla Biotech Holdings. Jupiter will pay PharmAla $3.3M upfront ($1.5M cash, $1.8M in Jupiter stock), plus $3.3M on first Phase III patient dosing and $20M on FDA NDA approval. ALA-002 targets PTSD, anxiety and other neuropsychiatric disorders.
4 min readJUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. STRATEGIC ASSET LICENSE AGREEMENT BETWEEN: PH
3 min readJupiter Neurosciences (JUNS) said it signed a definitive license with PharmAla Biotech (MDXXF) for perpetual exclusive U.S. rights to ALA-002, an FDA-designated NCE non-racemic MDMA formulation. Deal value is up to $100 million, including a $3.3 million upfront payment and up to $96.7 million in milestones, plus a 3% royalty on net sales. JUNS stock rose on the news.
4 min readJUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001679628 0001679628 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2026
2 min readJUPITER NEUROSCIENCES, INC. (JUNS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001679628 0001679628 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 17, 2026
3 min read
